Atopic dermatitis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 15: | Line 15: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! colspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ! colspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan=" | ! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
Line 24: | Line 24: | ||
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! colspan=" | ! colspan="6" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
Line 36: | Line 36: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nail pitting | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nail pitting | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! colspan=" | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ||
Line 48: | Line 48: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pustule | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pustule | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
|- | |- | ||
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders | ! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders | ||
Line 94: | Line 93: | ||
(Eosinophilia) | (Eosinophilia) | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 139: | Line 137: | ||
| align="center" style="background:#F5F5F5;" |Nl to ↑ | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
(Eosinophilia) | (Eosinophilia) | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
Line 173: | Line 170: | ||
* Dryness | * Dryness | ||
* Thicker skin | * Thicker skin | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 204: | Line 200: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 255: | Line 250: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 293: | Line 287: | ||
* Color of plaque varies fro, yellow to reddish brown | * Color of plaque varies fro, yellow to reddish brown | ||
* Plaque size can vary between 3X6 cm 6X10 cm areas. | * Plaque size can vary between 3X6 cm 6X10 cm areas. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 341: | Line 334: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin. | * Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 385: | Line 377: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Chronically lesions result into central clearing leading to annular lesions. | * Chronically lesions result into central clearing leading to annular lesions. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 438: | Line 429: | ||
* ↑ serum immunoglobulin E (IgE) levels | * ↑ serum immunoglobulin E (IgE) levels | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 476: | Line 466: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ||
Line 489: | Line 478: | ||
! rowspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ! rowspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dermatophyte|Dermatophytes]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dermatophyte|Dermatophytes]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 518: | Line 506: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Candidiasis|Candida]] | ! align="center" style="background:#DCDCDC;" |[[Candidiasis|Candida]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 547: | Line 534: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Herpes simplex]] | ! align="center" style="background:#DCDCDC;" |[[Herpes simplex]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 576: | Line 562: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Staphylococcus aureus]] | ! align="center" style="background:#DCDCDC;" |[[Staphylococcus aureus]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 628: | Line 613: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | | align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 656: | Line 640: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | +++ | | align="center" style="background:#F5F5F5;" | +++ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 675: | Line 658: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Human Immunodeficiency Virus (HIV)|HIV]] | ! align="center" style="background:#DCDCDC;" |[[Human Immunodeficiency Virus (HIV)|HIV]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 722: | Line 704: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ||
Line 758: | Line 739: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Oral manifestation such as vesicles and erosion may be present | * Oral manifestation such as vesicles and erosion may be present | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 808: | Line 788: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
| align="center" style="background:#F5F5F5;" | Thrombocytopenia | |||
| align="center" style="background:#F5F5F5;" | Thrombocytopenia | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
Line 869: | Line 848: | ||
* ↑ Eosinophilia | * ↑ Eosinophilia | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
Line 882: | Line 860: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[22q11.2 deletion syndrome|DiGeorge syndrome]] | ! align="center" style="background:#DCDCDC;" |[[22q11.2 deletion syndrome|DiGeorge syndrome]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 911: | Line 888: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Severe combined immunodeficiency]] ([[Severe combined immunodeficiency|SCID]]) | ! align="center" style="background:#DCDCDC;" |[[Severe combined immunodeficiency]] ([[Severe combined immunodeficiency|SCID]]) | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 940: | Line 916: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Ataxia telangiectasia]] | ! align="center" style="background:#DCDCDC;" |[[Ataxia telangiectasia]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 987: | Line 962: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ||
Line 1,000: | Line 974: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metabolic Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Metabolic Diseases | ||
! align="center" style="background:#DCDCDC;" |[[Phenylketonuria]] | ! align="center" style="background:#DCDCDC;" |[[Phenylketonuria]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,029: | Line 1,002: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Tyrosinemia]] | ! align="center" style="background:#DCDCDC;" |[[Tyrosinemia]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,058: | Line 1,030: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Histidinemia]] | ! align="center" style="background:#DCDCDC;" |[[Histidinemia]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,087: | Line 1,058: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Multiple carboxylase deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Multiple carboxylase deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,117: | Line 1,087: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional deficiencies | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nutritional deficiencies | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Zinc deficiency]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Zinc deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,146: | Line 1,115: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Pellagra|Niacin (B3) deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Pellagra|Niacin (B3) deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,175: | Line 1,143: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Pyridoxine deficiency|Pyridoxine (B6) deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Pyridoxine deficiency|Pyridoxine (B6) deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,204: | Line 1,171: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Biotin deficiency|Biotin (B7) deficiency]] | ! align="center" style="background:#DCDCDC;" |[[Biotin deficiency|Biotin (B7) deficiency]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,234: | Line 1,200: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cutaneous T cell lymphoma|Mycosis fungoides]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cutaneous T cell lymphoma|Mycosis fungoides]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,263: | Line 1,228: | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis|Histiocytosis X]] | ! align="center" style="background:#DCDCDC;" |[[Langerhans cell histiocytosis|Histiocytosis X]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,293: | Line 1,257: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Medications | ||
! align="center" style="background:#DCDCDC;" |[[Infliximab]] | ! align="center" style="background:#DCDCDC;" |[[Infliximab]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 1,341: | Line 1,304: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelets | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ESR/CRP | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Electrolytes |
Revision as of 21:27, 24 October 2018
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors forAtopic dermatitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Differentiating Atopic Dermatitis from other Diseases
Category | Diseases | Etiology | Inherited | Acquired | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History and risk factors | Symptoms | Physical examination | ||||||||||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||||||||||||
Appearance | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | CBC | ESR/CRP | Electrolytes | BUN/Cr | LFT | |||||||||||||||
Single/
Multiple |
Rash | Involved areas | Pustule | WBC | Platelets | ||||||||||||||||||||||
Skin disorders | Atopic dermatitis |
|
+ | + |
|
|
Multiple |
|
– | + | – | – | NA | – | – |
|
Nl to ↑
(Eosinophilia) |
Nl | Nl | Nl | Nl | Nl | Nl |
|
Clinical manifestation |
| |
Allergic contact dermatitis[1] |
|
– | + | Any |
|
May be multiple after 1-2 days of exposure | Erythematous well-demarcated papules | Surrounding the area in contact with the offending agent | – | + | – | – | Nl | + | – |
|
Nl to ↑
(Eosinophilia) |
Nl | Nl | Nl | Nl | Nl | NA | NA | Clinical manifestation + patch test |
| |
Irritant contact dermatitis[2] |
|
– | + | Any, more occupational exposure |
|
Usually single immediately after the exposure | Well-demarcated red patch with a glazed surface | Any area in contact with the irritant | – | + | – | – | Nl | + | – |
|
Nl | Nl | Nl | Nl | Nl | Nl | NA |
|
Clinical manifestation + patch test |
| |
Seborrheic dermatitis |
|
– | + | Any, onset during the 1st days or weeks of life |
|
Greasy scaling on a yellow-red base | Scalp, axilla, and diaper area | – | |||||||||||||||||||
Psoriasis |
|
+ | + | Any, 2 peaks of onset 30-39 years and 50-59 years |
|
Multiple | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales |
|
+ | + | +
Auspitz sign (pinpoint bleeding) |
_ | Nl | + | + | ||||||||||||
Lichen simplex [3]chronicus |
|
– | + | Any, peak at 30-50 years of age |
|
Multiple | Lichenified and erythematous, pruritic exudative plaque, and excoriations | Scalp, head, neck, hands, arms, and genitals areas | – | + | – | – | Nl | – | – |
|
Nl | Nl | Nl | Nl | Nl | Nl | Nl |
|
Clinical manifestation |
| |
Ichthyosis vulgaris[4] |
|
+ | + | Usually in infancy |
|
Multiple |
|
|
– | – | – | – | Nl | – | – |
|
Nl | Nl | Nl | Nl | Nl | Nl | Nl |
|
Clinical manifestation |
| |
Nummular dermatitis (discoid eczema) | Unknown | – | + | Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females |
|
Multiple | Nl |
|
– | + | – | – | Nl | – | – |
|
Nl | Nl | Nl | Nl | Nl | Nl | Nl |
|
Clinical manifestation |
| |
Netherton's syndrome[5] | Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (SPINK5), encoding LEKTI, a serine protease inhibitor | + | – | Affects neonates |
|
Multiple |
|
|
+ | + | – | – | Nl | – | – |
|
|
Nl | Nl | Nl | Nl | Nl | Nl |
|
Clinical manifestation |
| |
Diseases | Etiology | Inherited | Acquired | Demography | History and risk factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings | |
Infection | Dermatophytes | ||||||||||||||||||||||||||
Candida | |||||||||||||||||||||||||||
Herpes simplex | |||||||||||||||||||||||||||
Staphylococcus aureus | |||||||||||||||||||||||||||
Molluscum contagiosum | Molluscum contagiosum virus inoculation through direct skin contact | – | + | Any, peak among children >5 years of age and young adults |
|
Multiple |
|
|
– | + | – | – | Nl | – | – | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | Nl | Nl | Nl | Nl | Nl | Nl | Nl |
|
Clinical manifestation | mMlluscum contagiosum
lesions on the eyelid may lead to follicular or papillary conjunctivitis . | |
Scabies |
|
Multiple | Erythematous papular lesions | Flexor wrists, finger webs and genitalia | +++ | ||||||||||||||||||||||
HIV | |||||||||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | History and risk factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings | |
Immunologic disorders | Dermatitis herpetiformis[6] | Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies | – | + | Any, mean age of disease onset is 2nd-4th decade |
|
Multiple |
|
|
– | + | – | – | Nl | – | – |
|
Nl | Nl | Nl | Nl | Nl | Nl | Nl |
|
Direct immunofluorescence microscopy (DIF) - presence of granular deposits of IgA within the dermal papillae |
|
Immune deficiency | Wiskott-Aldrich syndrome[7] |
|
+ | – | Seen almost exclusively in males in infancy |
|
Multiple |
|
Rash can involve lesions located at the same areas of classical atopic dermatitis:
extensor surfaces of extremities and cheeks or scalp |
– | + | + | – | Nl | – | – | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising |
|
Thrombocytopenia | Nl | Nl | Nl | Nl | Nl |
|
Clinical manifestation |
|
Hyper-IgE syndrome[8] |
|
+ | – | Rare, begin in infancy |
|
Multiple |
|
|
+ | + | – | – | Nl | – | – |
|
|
Nl | Nl | Nl | Nl | Nl | Nl |
|
Clinical and laboratory findings |
| |
DiGeorge syndrome | |||||||||||||||||||||||||||
Severe combined immunodeficiency (SCID) | |||||||||||||||||||||||||||
Ataxia telangiectasia | |||||||||||||||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | History and risk factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings | |
Metabolic Diseases | Phenylketonuria | ||||||||||||||||||||||||||
Tyrosinemia | |||||||||||||||||||||||||||
Histidinemia | |||||||||||||||||||||||||||
Multiple carboxylase deficiency | |||||||||||||||||||||||||||
Nutritional deficiencies | Zinc deficiency | ||||||||||||||||||||||||||
Niacin (B3) deficiency | |||||||||||||||||||||||||||
Pyridoxine (B6) deficiency | |||||||||||||||||||||||||||
Biotin (B7) deficiency | |||||||||||||||||||||||||||
Malignancy | Mycosis fungoides | ||||||||||||||||||||||||||
Histiocytosis X | |||||||||||||||||||||||||||
Medications | Infliximab | ||||||||||||||||||||||||||
Category | Diseases | Etiology | Inherited | Acquired | Demography | History | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | BP | Tenderness | Nail pitting | Other | WBC | Platelets | ESR/CRP | Electrolytes | BUN/Cr | LFT | Imaging | Histopathology | Gold standard | Additional findings |
References
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
- ↑ Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.
- ↑ Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G (July 2017). "Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade". Open Access Maced J Med Sci. 5 (4): 556–557. doi:10.3889/oamjms.2017.133. PMC 5535688. PMID 28785363.
- ↑ Thyssen JP, Godoy-Gijon E, Elias PM (June 2013). "Ichthyosis vulgaris: the filaggrin mutation disease". Br. J. Dermatol. 168 (6): 1155–66. doi:10.1111/bjd.12219. PMID 23301728.
- ↑ Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (June 2000). "Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome". Nat. Genet. 25 (2): 141–2. doi:10.1038/75977. PMID 10835624.
- ↑ Kárpáti S (2012). "Dermatitis herpetiformis". Clin. Dermatol. 30 (1): 56–9. doi:10.1016/j.clindermatol.2011.03.010. PMID 22137227.
- ↑ Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
- ↑ Mogensen TH (April 2013). "STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties". JAKSTAT. 2 (2): e23435. doi:10.4161/jkst.23435. PMC 3710320. PMID 24058807.